Phase 2 N=27 Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Hypoparathyroidism
Primary: Serum Calcium Level — 2; 1.92 mmol/liter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=151 Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
Hepatitis C Virus
Primary: Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 2 — 83.3; 82.6; 62.5 percentage of…
Phase 4 N=128 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
Acromegaly
Primary: Percentage of Subjects Having Maintained Their Injection Interval Schedule of Six Weeks or Increased Their Injection Interval to Eight Weeks Whilst Keeping Their…
Phase 1 N=41 EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases
Colorectal and Ovarian Cancer Patients With Liver Metastases
Primary: Number of Subjects With Dose Limiting Toxicities (DLTs) — 1; 1; 0; 2 Subjects
Phase 3 N=490 A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation) — -0.84; -0.92; -0.70 units on…
Phase 3 N=333 Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Phase 2 N=30 Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer
Head and Neck Neoplasms
Primary: Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site — 76.7 percentage of participants
Phase 3 N=19 A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
Gaucher Disease
Primary: Spleen Volume — 2032.0; 1960.0; 2321.7; 1522.6 Milliliters
Phase 4 N=26 Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Coronary Artery Disease · Type 1 Diabetes Mellitus
Primary: Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects. — 2.19; 1.81; 1.95 percentage of StressMBF/ Rest…
Phase 2 N=180 EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Prostate Cancer Metastatic
Primary: Progression Free Survival (PFS) Time — 3.3; 3.4; 4.3 months
Phase 3 N=58 A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Number of Patients With Adverse Events and Adverse Drug Reactions — 37; 2 participants
Phase 3 N=5 Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
Gaucher Disease
Primary: Number of Participants With Drug-related Adverse Events (AEs), Infusion-related AEs, and Serious AEs (SAEs) — 2; 0; 2 participants
N/A N=443 An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) — 38.7 percentage of participants
Phase 2 N=63 The HEALS Project - Health Education and Active Living for Surviving Seniors
Cancer Survivorship · Safety and Efficacy · Quality of Life
Primary: Retention Rates and Class Attendance — 91; 81; 79; 83 percentage of participants
Phase 2 N=384 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Cell Carcinoma · Cervical Small Cell Carcinoma
Primary: The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Abdomen — 50; 65 percentage of participants